A 52-year-old man with chronic kidney disease (eGFR 28 mL/min/1.73 m²) and peripheral arterial disease presents with claudication. Digital subtraction angiography (DSA) of the lower limbs is planned. Which of the following is the MOST appropriate intervention to minimize contrast-induced nephropathy (CIN) while maintaining diagnostic image quality?

Explanation

## Contrast-Induced Nephropathy Prevention in High-Risk Patients ### Risk Stratification **Key Point:** This patient has eGFR 28 mL/min/1.73 m² — advanced CKD Stage 4 — placing him at high risk for CIN (incidence 10–25%). Two critical decisions must be made: (1) contrast medium selection, and (2) metformin management. ### Why Option D is Correct **High-Yield:** The evidence-based standard of care for CIN prevention in advanced CKD involves: 1. **Contrast medium selection:** Both IOCM (iso-osmolar, ~290 mOsm/kg) and LOCM (low-osmolar, 600–850 mOsm/kg) are acceptable; IOCM may offer marginal benefit in severe CKD. HOCM (>1200 mOsm/kg) is contraindicated in advanced CKD due to high tubular toxicity. 2. **Hydration strategy:** High-volume intravenous normal saline (0.9% NaCl, 1–1.5 mL/kg/hr for 3–12 hours before and 6–12 hours after) is the **cornerstone** of CIN prevention per current ACC/AHA and ESUR guidelines. While sodium bicarbonate was once favored, the landmark PRESERVE trial (NEJM 2018) demonstrated **no superiority of sodium bicarbonate over normal saline** for CIN prevention. Normal saline remains the standard hydration fluid [Harrison's 21e, Ch. 277; PRESERVE Trial, NEJM 2018]. 3. **Metformin management:** This is the critical differentiator. In patients with eGFR <30 mL/min/1.73 m² (or any patient receiving iodinated contrast), metformin **must be held for 48 hours post-procedure** due to the risk of contrast-induced AKI leading to metformin accumulation and potentially fatal **lactic acidosis**. This is a firm recommendation from the FDA, EMA, and major nephrology/radiology guidelines [KD Tripathi 8e, Ch. 48; ACR Manual on Contrast Media 2023]. This patient's eGFR of 28 is already below the threshold — metformin should be withheld. ### Why the Other Options Are Incorrect - **Option A (HOCM + NAC):** HOCM is contraindicated in advanced CKD. NAC has no proven benefit over hydration alone in modern practice (meta-analyses, including PRESERVE trial). - **Option B (CT angiography):** CT angiography uses the same iodinated contrast load and confers equivalent CIN risk. Deferring DSA delays treatment of symptomatic PAD without reducing nephrotoxicity risk. - **Option C (LOCM + sodium bicarbonate + continue metformin):** Two errors: (1) Sodium bicarbonate is NOT superior to normal saline (PRESERVE trial); (2) Continuing metformin in a patient with eGFR 28 receiving contrast is dangerous — metformin must be held 48 hours post-procedure. ### Clinical Algorithm | Parameter | Correct Approach | |-----------|-----------------| | Contrast medium | IOCM or LOCM (never HOCM in CKD) | | Hydration | High-volume normal saline IV | | Metformin | **Hold 48 hours post-procedure** | | NAC | Not routinely recommended | **Clinical Pearl:** The two most commonly tested facts in CIN prevention are: (1) **normal saline is equivalent to sodium bicarbonate** (PRESERVE trial), and (2) **metformin must be held** post-contrast in patients with CKD or risk of AKI to prevent lactic acidosis — this applies especially when eGFR <30 mL/min/1.73 m².